Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 526 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy MOST POPULAR More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections June 3, 2022 Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... April 22, 2021 Good-bye, Old Friend January 8, 2021 NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted... April 13, 2022 Load more HOT NEWS Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... Qué debo saber sobre la mastectomía con cierre plano después de...
